4.
Biermann W.A., Cantor R.I., Fellin F.M., Jakobowski J., Hopkins L.,
Newbold R.C.
An evaluation of the potential cost reductions resulting
from the use of clodronate in the treatment of metastatic carcinoma of
the breast.//Bone. — 1991. — 12. — pp.37/42.
5.
Boyce B.
Effects of metastatic tumors on the skeleton.//ASCO. —
Educational book. — 1998. — pp.11/15.
6.
Chigira M., Watanabi J. et al.
Pain and internal hypertension in bone
lesions.//Acta.Orth.Scand. — 1984. — 55. — pp.375/377.
7.
Coleman R.E., Rubens R.D.
The clinical course of bone metastases from
breast cancer.//Br.J.Cancer. 1987. — 55. — pp.61/66.
8.
Coleman R.E., Paterson A.H., Conte P.F., Tyrrell C.J., Walls J., Hender(
son M.A. et al.
Advances in the management of metastatic bone dis/
ease.//The breast. — 1994. — 3. — pp.181/185.
9.
Eilon G., Mundy G.R.
Direct resorption of bone by human breast cancer
cells in vitro.//Nature. — 1978. — 276. — pp.726/728.
10.
Elomaa I., Blomqvist C.
Clodronate and other bisphosphonates as sup/
portive therapy in osteolysis due to malignancy.//Acta.Oncol. — 1995. —
34. — pp.629/636.
11.
Eriksen E.F., Kassem M.
The cellular basis of bone remodeling.//
Triangle. — 1992. — 31. — pp.45/57.
12.
Fidler M.
Incidence of fracture through metastases in long bones.//Acta.
Orthop.Scand. — 1987. — 52. — pp.623/627.
13.
Galasko C.S.
Incidence and distribution of bone metastases.//Clin.
Orthop. — 1986. — 210. — pp.14/21.
14.
Garrett R.I.
Bone destruction in cancer.//Sem.Oncol. — 2. — suppl.2. —
pp.4/9.
15.
Hillner B., Ingle J., Berenson J. et al.
American Society of clinical
Oncology Guiedline on the Role of Bisphosphonates in Breast
Cancer.//JCO. — 2000. — vol.18. — N6. — pp.1378/1391.
16.
Holick M.F., Krane S.M., Potts J.T.
Calcium, phosphorus and bone
metabolism: calcium/regulating hormones.//In: Harrison's Principles
of internal medicine. — 12th ed. — Ed.J.Wison et al. — pp.1888/
1902.
17.
Huggia F.M.
Overview of cancer related hypercalcaemia: epidemiology
and etiology.//Semin.Oncol. — 1990. — 17. — pp.3/9.
18.
Kanis J.A., O'Rourke N., McCloskey E.
Consequences of neoplasia
induced resorption and the use of clodronate (Review).//Int.J.Oncol. —
1994. — 5. — pp.713/731.
19.
Kylmala T., Tammela T., Risteli L., Risteli I., Taube T. et al.
Evaluation
of the effect of oral clodronate on skeletal metastases with type I colla/
gen metabolites. A controlled trial of the Finnish prostate cancer
group.//Eur.J.Cancer. — 1993. — 29. — A. — pp.821/825.
20.
Mason M.D., Glaholm J., Dearnaley D.P.
The use of bisphosphonates in
prostatic cancer.//Clin.Oncol. — 1994. — 6. — pp.77/78.
645
Êóðñ ëåêöèé ïî ïàëëèàòèâíîé ïîìîùè îíêîëîãè÷åñêèì áîëüíûì. Òîì I
